Xifeng Huashi significantly improves mental status and clinical symptoms in patients diagnosed with IBS-D and helps reduce relapse rates.
The observed improvement in patients indicates a notable enhancement in their overall quality of life with this treatment.
Assessment included tracking clinical symptoms and measuring mental status over a defined treatment period.
The findings highlight the need for further validation and could guide future treatment approaches for IBS-D patients.
Abstract
Xifeng Huashi is effective for the treatment of IBS-D and manifests advantages in improving clinical symptoms and mental status, as well as reducing the short-term relapse rate.